Index to volume 65 Author index Blum RA (see Chakraborty et al). 1999;65:304-18 Bochner F (see Dyer et al). 1999:65:685-94 Aarons L (see Gupta et al). 1999;65:672-84 Branch RA (see Bluhm et al). 1999:65:598-605 Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns Breil M (see Sanquer et al). 1999:65:640-8 GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo Bremer F (see Teg tt al). 1999;65:50-7 1999:65:465-72 Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy Abernethy DR (see Jones et al). 1999;65:408-12 KC, Aweeka FT. Pharmacokinetics of cidofor Abernethy DR (see Schulman et al). 1999;65:593-7 ciency and in continuous ambulato1 Abolfathi Z (see Yacobi et al). 1999;65:389-94 hemodialysis. 1999;65:21-8 Adcock S (see Schwartz et al). 1999:65:653-60 Brune K (Sée Tegeder et al). 1999:65 Addison RS (see Gross et al). 1999:65:395-401 Brune K (see Tegeder et al). 1999:65 Adedoyin A (see Bluhm et al). 1999;65:598-605 Brune K (see Tegeder et al). 1999;65 Agostoni P (see Guazzi et al). 1999;65:319-27 Budde K (see Miick et al). 1999;65:251 Agundez JA (see Martinez et al). 1999:65:369-76 Buemi M, Allegra A, Corica F, Rt AlbetC (see Martinez et al). 1999;65:369-76 Giacobbe MS, Romeo A, Frisina N Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, tion on blood bc/-2 concentrations 1 vith immunoglobulin Schwilden H, Schiittler J. The effect of age on the pharmacokinetics \ nephropathy. 1999;65:649-52 and pharmacodynamics of midazolam. 1999;65:630-9 Bukowski R (see Rakhit et al). 1999:65:615-29 Aleman C (see Mas et al). 1999;65:439-47 Bulitta J (see Kinzig-Schippers et al). 1999;65:2K6I2.-77A4 Alisi C (see Buemi et al). 1999;65:649-52 Allegra A (see Buemi et al). 1999;65:649-52 Andrawis NS (see Jones et al). 1999;65:408-12 Aravind MK (see Kauffman et al). 1999;65:382-8 Ariyoshi N (see Tateishi et al). 1999;65:570-5 aracoY (see Sviri et al). 1999;65:275 Arvieux C (see Michelet et al). 1999;65:661-71 ‘arcas AJ, Garcia-Satué JL, Zapater ta J. Tobramycin Astier A (see Sanquer et al). 1999;65:640-8 penetration into epithelial lining ft patients v nonia Atkinson AJ (see Shepherd and Atkinson). 1999;65:355-6 1999:65:245-50 Carrillo JA (see Martinez et al). 1999;65:369-76 (Commentary ) Cartier F (see Michelet et al). 1999;65:661-71 Aweeka FT (see Brody et al). 1999;65:21-8 \ziz M (see Massien et al). 1999;65:448-59 Carvajal DM (see Rakhit et al). 1999;65:615-29 Cassel W (see Heitmann et al). 1999;65:328-35 B Castano G (see Mas et al). 1999:65:439-47 Chakraborty A, Blum RA, Cutler DL, Jusko WJ. Pharm: Bachmann KA (see Schwartz et al). 1999;65:653-60 dynamic interactions of interleukin-10 and prednisone in Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, volunteers. 1999:65:304-18 Hendrix CW, Flexner C. The effects of rifampin and rifabutin on the ‘halon S, Bedarida GV, Moreno H, Tejura B pharmacokinetics and pharmacodynamics of a combination oral Blaschke TF. Inhibition of angiotensin-conve contraceptive. 1999;65:428-38 hand veins. 1999:65:58-65 Barennes H (see Pussard et al). 1999:65:500-10 halon S, Moreno H, Hoffman BB, Blaschke Baron C (see Sanquer et al). 1999;65:640-8 verting enzyme inhibition improves v Bauer S (see Miick et al). 1999;65:251-61 in chronic smokers. 1999:65:295-303 Bazin C (see Michelet et al). 1999:65:661-71 ‘han CC (see Schwartz et al). 1999:65:653-60 Beaver WT (see Wideman et al). 1999:65:66-76 “*hauvin JP (see Michelet et al). 1999:65:661 Bedarida GV (see Chalon et al). 1999:65:58-65 heng CL (see Huang et al). 1999;65:402-7 Beerahee M (see Hussein et al). 1999:65:1-9 da M (see Tateishi et al). 1999:65:570-5 Beglinger C (see Drewe et al). 1999;65:413-9 ‘horazyczew ski J (see Gros et al 1999:65:545-51 Bellisant E (see Michelet et al). 1999:65:661-71 ‘huang SK (see Huang et al). 1999;65:402-7 Benitez J (see Martinez et al). 1999;65:369-76 ‘lavier F (see Pussard et al). 1999:65:500-10 Benovic JL (see Gros et al). 1999;65:545-51 ohen RA (see Schwartz et al). 1999;65:653-60 Berndt A (see Scwarz et al). 1999:65:283-29 olaizzi JL (see Yacobi et al). 1999:65:389-94 Bickel U (see Heitmann et al). 1999:65:328-35 ‘olburn W (see Scheffler et al). 1999:65:483-90 Bjornsson T (see McCrea et al). 1999:65:348-52 ‘olice G (see Hussein et al). 1999;65:1-9 Blaschke TF (see Chalon et al). 1999:65:58-65 ‘oresh J (see Barditch-Crovo et al). 1999:65:423-38 Blaschke TF (see Chalon et al). 1999;65:295-303 ‘orica F (see Buemi et al). 1999:65:649-5 Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Development of ‘ribb A (see McCrea et al). 1994;65:348-52 dapsone toxicity in patients with inflammatory dermatoses: activity ‘undy KC (see Brody et al). 1999:65:21-8 of acetylation and hydroxylation of dapsone as risk factors ‘utler DL (see Chakraborty et al). 1999:65:304-18 1999:65:598-605 RA‘AAz RajAa-RBAulRsaA RGA R(sRee ARGaAwRroAnRsAkaA-RSzAkDlaLrAzD et al). 1999:65:562-9 D eeeeeee e January, pp. 1-116; February, pp. 117-234; March, pp. 235-354; April, pp. 355-464; May, pp. 465-592; June, pp. 593-716. Index to the Dallaire BK (see de Jonge et al). 1999;65:491-9 ASCPT meeting abstracts is located in the February issue Dallob A (see Ehrich et al). 1999:65:336-47 CLINICAL PHARMACOLOGY & THERAPEUTICS JUNE 1999 705 1900 999-65 1999-65:630-9 CLINICAL PHARMACOLOGY & THERAPEUTICS 708 Author index JUNE 1999 McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Peter JH (see Heitmann et al). 1999;65:328-35 Waldman S, Bjornsson T, Speilberg S, Goldberg MR. Phenotypic and Pettinato G (see Buemi et al). 1999;65:649-52 genotypic investigations of a healthy volunteer deficient in the con Pontigas V (see Mas et al). 1999;65:439-47 version of losartan to its active metabolite E-3174. 1999;65:348-52 Porras A (see Ehrich et al). 1999:65:336-4 Mehlisch DR (see Ehrich et al). 1999:65:336-47 Presky DH (see Rakhit et al). 1999;65:615-29 Mehta R (see Yacobi et al). 1999:65:389-94 Proost JH. Do computational results depend on PC processors? Meller S (see Tegeder et al). 1999;65:357-68 1999:65:460 (Letter) Melzi G (see Guazzi et al). 1999:65:314 9-2 Pussard E, Barennes H, Daouda H, Clavier F, Sani AM, Osse M, Ménard J (see Massien et al). 1999:65:448 Granic G, Verdier F. Quinine disposition in globally malnourishea Menelaou A (see¢ Dyer et al). 1999:65:685-94 children with cerebral malaria. 1999;65:500-10 Michelet C, Beilisant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, , Renard I, Sebille V, Chauvin JP, Dohin E, Cartier F. Safety and efficacy of retonavir and saquinavir in combination with zidovu R and lamivudine. 1999;65:661-71 ra K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima | Raffi F (see Michelet et al). 1999;65:661-71 Otani K, Kaneko S, Inoue Y. Effects 1e CYP2D6*/0 allele on the Rakhit A, Yeon MM, Ferrante J, Fettner S$, Nadeau R, Motzer R Steady-state plasma concentrations of haloperidol and reduced Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, Magram J, haloperidol in Japanese patients with schizophrenia. 1999;65:291-4 Gately MK. Down-regulation of the pharmacokinetic-pharmacody- Mizorogi Y (see Tateishi et al). 1999;65:570-5 namic response to interleukin-12 during long-term administration to Mohamed MHN (see Lima et al). 1999;65:519-25 patients with renal cell carcinoma and evaluation of the mechanism Moreno H (see Chalon et al). 1999:65:58-65 of this “adaptive response” in mice. 1999;65:615-29 Moreno H (see Chalon et al). 1999:65:295-303 Ramirez J (see lyer et al). 1999;65:576-82 MoritzC (see Schwartz et al). 1999:65:653-60 Ratain MJ (see lyer et al). 1999;65:576-82 Moros D (see Yacobi et al). 1999:65:389-94 Rathore SS (see Schulman et al). 1999:65:593 Morris E (see Wideman et al 1999-65:66-76 Rei:d enberg : MM. New headings for the table of contents. 1999:65:2 Mortell MA (see lyet 1999-65:576~ -8 ) MottetC (see Drewe 1999-65:413-9 Renard I (see Michelet et al). 1999;65:661 Motzer R (see Rakhit et al). 1999;65:615 Rider MJ (see Tschen et al). 1999:65:526-32 Miick W, Mai I, Fritsche | Riendeau D (see Ehrich et al). 1999;65:336-4 Baue Rocco LE (see Barditch-Crovo et al). 1999;65:423-38 cerivastatin systemic exposure after single and multiple dosing in Rohde G (see Miick et al). 1999;65:251-61 cyclosporine-treated kidney transplant recipients. 1999;65:251-61 Romeo A (see Buemi et al). 1999:65:649 Muir KT (see Hermann et al 1999:65:511-8 Roots I (see Miick et al). 1999:65:251-61 Mukhopadhyay S 1999:65:653-60 see Buemi et al). 1999:65:649-52 Muth-SelbachU ( -9eder et al). 1999:65:357-68 ault A (see Michelet et al). 1999:65:661-71 Muth-Selbach U (s¢ »geder et al). 1999:65:533-44 Rushmore T (see McCrea et al). 1999:65:348-52 Riising G (see Kinzig-Schippers et al). 1999:65:262-74 Riising G (see Tegeder et al). 1999:65:357-68 15.99 tal). 1999-65-29] 999-65:-606 19909-65:-990.39 } P cede et al 000-65-5( 1999-65:500-10 umayer HH (see il). 1999:65 Dhamane D, Astier A, Lang 1en PJ, Kantola Kivist6 KT lase activity aft ista II [t eraction. 1999:65:583 (1L et vith mycophenolate mofetil. 1999;65:640-8 uvonen PJ (see Villikka et al). 1999;65 see Gupta et al). 1999;65:672-84 shimoto M (see Furuta et al 999-65°559 Scheffler MR, Colburn W, Ko not alter estrogen-progesteron 1999:65:2 1999-65:- 14 999-65:2 al). 1999:65:237-44 1999-65:357 DR, Rathore SS, Woosley RI 1999-65:283 manufacture! communication in the information 1999-65:552-61 1999-65:593 999-65:369 1999-65:630-9 ea et al | 1999-65-34 +O Mukhopadhyay S, McBride K, Jones TM, al 1999:65:500-10 S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA, 1999-65:291-4 vidson MH, Bachmann KA, Gertz BJ. Cyclooxy ase-2 inhibi ] 1999:65:5 ion by rofecoxib reverses naturally occurring fever in humans 1999:65:653-60 Schwilden H (see Albrecht et al). 1999;65:630-9 P Scwarz UI, Gramatté T, Krappweis J, Berndt A, Oerte! R, von Richter O, Kirch W. Unexpected effect of verapamil on oral bioavailability \ message from the President: The Centennial ASCPT meet of the B-blocker talinolol in humans. 1999;65:283-290 ng—Come to San Antonio, March 18-20, 1999. 1999:65:80 Sebille V (see Michelet et al). 1999;65:661-71 Penzel T (see Heitmanent al). 1999:65:328-35 Seibold JR (see Ehriect hal) . 1999:65:336 PHARMACOLOGY & 65, NUMBER 6 Author index 709 Self TH (see Lima et al). 1999;65:519-25 9 Sheiner LB (see Gupta et al). 1999;65:6 Shenfield GM (see Gross et al). 1999:65 395-401 Van Hecken A (see Ehrich et a 199-65 Shepherd AMM, Atkinson AJ. Report from the American Board Vega JM (see Tobert et al 999-65:583 (I Clinical Pharmacology. 1999;65:355 6 (Commentary Pussard et al). 1999;65:500 Shin JG (see Ko et al). 1999:65:606-14 de Jonge et al). 1999;65:49 Shin SG (see Ko et al). 1999:65:606-14 Vesterqvist O (see Massien et al). 1999-65 Shpizen S (see Sviri et al). 1999;65 27—e 5 On Villikka K, Kivist6 KT, Neuvonen PJ. The Sieber CC (see Drewe et ual l). 1999;6 5:413-9 t of oral a Somogyi AA (see Dyer et al). 1999:65:685-94 Hussein Sérgel F (see Kinzig-Schippers et al). 1999;65:262 é SoérgelF (see Teged t al 1999-65:357-68 Sparreboom A (s¢ e et al). 1999;65:491-9 Speilber S (see McCrea et al 1999-65:348-52 Suzuki A (see Mihara et al). 1999;65:291-4 Sviri S, Shpizen S, Leiersdorf E, Levy M, CaracoY . Pheno 1900-65-24 typic analysis of CYP2C19 in the Je Israel 100-465 1999-65:275-82 - 199-65 99-65 HAalSesic Cll ica 1999-65:552 1 postoperative pain it e Gros et al). 1999:65:545-5 1 ilkinsoVnL (see Rakhit et al 999:65 hida M, Ariyoshi N, Mizor ilson DI ee ree t ; 999-65 > CYP2D6 gene in relat I to dextromet 9909-65-57 Subject index Analgesia Characterization of rofecoxib as a cyclooxygenase-2 isoform Acetylation inhibitor and demonstration of analgesia in the dental pain model patients with inflammatory der (Ehrich et al). 1999:65:336-47 activity of acetylation and hydroxylation of dapsone as Analgesics, non-narcotic (Bluhm et al). 1999:65:598-605 Analgesic efficacy of a combination of hydrocodone with ibuprofen yetween acetylation polymorphism and risk of atopic in postoperative pain (Wideman et al). 1999;65:66-76 liseases (Gawrodanska-Szkla 1999:65:562-9 Analgesics, opioid Acid-base equilibrium Analgesic efficacy of a combination of hydrocodone with ibuprofen Cryrp zC/Y genotype status al t of omeprazole on intragastric in postoperative pain (Wideman et al). 1999;65:66-76 pH in humans (Furuta et ¢ 1999:65:552-61 Ancestim Administration, topical Ancestim (USAN List No. 414). 1999;65:462 Application of microdialysis for the determination of muscle and Anecortave acetate subcutaneous tissue concentrations after oral and topical ibupro Anecortave acetate (USAN List No. 415). 1999;65:592 en administration (Tegeder et al). 1999;65:357-68 A ngiotensin-converting enzyme inhibitors Adrenergic beta blockers Angiotensin-converting enzyme inhibition facilitates alveolar-capil Unexpectc bioavailability of the B lary gas transfer and improves ventilation-perfusion coupling in 1999-65:283-290 patients with left ventricular dysfunction (Guazzi et al). 1999;65 319-27 ramipril on sympathetic nervous system function in al). 1999:65:420-7 Angiotensin-converting enzyme inhibition improves venous Age factors endothelial dysfunction in chronic smokers (Chalon et al). 1999; The effect of age on the pharmacokinetics and pharmacodynamics 65:295-303 of midazolam (Albrecht et al). 1999;65:630-9 Inhibition of angiotensin-converting enzyme in human hand veins Ag ranulocytosis (Chalon et al). 1999:65:58-65 Phe cytotoxicity of clozapine metabolites: implications for predicting Pharmacodynamic effects of dual neutral endopeptidase cloZapine ed agranulocytosis (Tschen et al). 1999:65:526-32 angiotensin-converting enzyme inhibition versus angiotensin Albuterol converting enzyme inhibition in humans (Massien et al). 1999; polymorphisms of the {5,-adrenergic receptor on 65:448-59 chodilator pharmacodynamics (Lima et al). 1999; Aniline compounds Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568 (Lalonde et al). 1999;65:40-9 USAN List No. 416). 1999:65:697 Arzoxifene hydrochloride AAliy notriptan malate Arzoxifene hydrochloride (USAN List No. 416). 1999;65:700 Almotriptan malate (USAN List No. 416). 1999:65:697 Avasimibe American Board of Clinical Pharmacy Avasimibe (USAN List No. 414). 1999:65:462 Report from the American Board of Clinical Pharmacology Shepherd and Atkinson). 1999:65:355-6 (Commentary American Society for Clinical and Pharmacology and Therapeutics B Abstracts of annual meeting. 1999;65:117-234 Election of Officers and Committe Chairpersons for 1999-2000 bel-2. see Proto-oncogene proteins c-bel-2 1999:65:695 Bexarotene program. 1999:65:80-116 Bexarotene (USAN List No. 414). 1999:65:462 ge from the Membership Committee Chair (Jones) Biological availability 999:65:586-9 Unexpected effec verapamil on oral bioavailability of the from the SI > Centennial ASCPT meeting 1999 (Peck). 1999:65:80 (-blocker talinolol in humans (Schwarz et al). 1999:65:283-290 Blacks n Committee Chairperson Impaired endothelial-dependent forearm vascular relaxation in black ission of abstracts for the 2000 annual meeting (Carruthers Americans (Jones et al). 1999;65:408-12 1999:65:696 Future meeting dates and sites of the ASCPT. 1999:65:696 Blood pressure 9-Amnocamptothecin Does short-term treatment with modafinil affect blood pressure in Clinical pharmacokinetics of encapsulated oral 9-aminocamp patients with obstructive sleep apnea? (Heitmann et al). 1999; 65:328-35 tothecin in plasma and saliva (de Jonge et al). 1999;65:491-9 Amoxicillin sodium Impaired endothelial-dependent forearm vascular relaxation in black Amoxicillin sodium (USAN List No. 415). 1999:65:592 Americans (Jones et al). 1999;65:408-12 Amprenavir Bradykinin Amprenavir (USAN No. 416). 1999:65:702 Inhibition of angiotensin-converting enzyme in human hand veins (Chalon et al). 1999;65:58-65 Bronchodilator agents January, pp. 1-116; February, i pp. 11 ch, pp. 235-354; April Impact of genetic polymorphisms of the f>-adrenergic receptor on pp. 355-464; May, pp. 465-592; June 593-716. Index to the albuterol bronchodilator pharmacodynamics (Lima et al). 1999; ASCPT meeting abstracts is located in the February issue 65:519-25 710 JUNE 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS Cyclosporine TD ‘alcium Mixed-effects modeling of cimi. metic agentnt RK -508 ‘ ‘alcium channel blockers alfactant Calfactant (USAN List arbamazepine P45( e CYPIA2 (K 65 329.904 Cytochrome P450 CYP3A arcinoma, renal cell Down-regulatio Cytochrome P450 CYP3A4 ‘aspofungin acetate I ) Caspofun in acetal USAN I ‘erebral malaria. see Malaria, cerebral Cytochrome P450 CYP2C19 ‘erivastatin YP2C19 genotype stat H Cytochrome P450 CYP2D6 Cri dD hinese Pha ‘isapride Influence of 1). 1999-65 ‘larithromycin ( hrome (Desta et 99 linical Pharmacology and Therapeutics linical pharmacy S| Cytosine lozapine ‘olesevelam hydrochloride Colese ‘ommentaries Commentaries Dapsone ommunication ) R ‘ NCE i lid tion age (Schuln S (Db ‘omputers. see Microcomputers Darbufelone mesylate ontinuous ambulatory peritoneal dialysis. Peritoneal dialysis, ID YI continuous ambulatory Depreotide ‘ontraceptives, oral Dept t LIS + \ N\I ] st \ N Dermatoses. Skin diseases pharmacodyn Desloratadine Barditch-Crovo Picclowimaiers SAN ‘oronary disease Dextromethorphan Effec> ts of pYolli icosan'o l 1 iniy p+a9 tien*y ts witith h txt ype and additional coronary risk factors (Mas yclooxygenase. see Prostaglandin endoperoxide synthase eneearr ee CLINICAL PHARMACOLOGY & THERAPEUTICS 712 Subject index JUNE 1999 Diclofenac Phenotypic and genotypic investigations of a healthy volunteer defi- Comparison of inhibitory effects of meloxicam and diclofenac on cient in the conversion of losartan to its active metabolite E-3174 human thromboxane biosynthesis after single doses and a steady (McCrea et al). 1999;65:348-52 state (Tegeder et al). 1999;65:533-44 Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli Drospireone population (Sviri et al). 1999;65:275-82 Drospireone (USAN List No. 412). 1999;65:79 Glomerulonephritis, IGA Drug evaluation Effects of lisinopril administration on blood bc/-2 concentrations in Regulating manufacturer-affiliated communication in the informa patients with immunoglobulin A nephropathy (Buemi et al) ion age (Schulman et al). 1999;65:593 1999:65:649-52 Drug interactions G-proteins channel blocker-simvastatin interaction (Tobert et al) G-protein-coupled receptor kinase expression in hypertension (Gros Neuvonen et al) (Reply). 1999:65:583 et al). 1999;65:545-51 immunodynamic interactions of interleukin-10 and pred Grapefruit juice >in healthy volunteers (Chakraborty et al). 1999;65:304-18 6’,7’-Dihydroxybergamottin in grapefruit juice and Seville orange Drug metabolism juice: effects on cyclosporine disposition, enterocyte CYP3A4, P \tiomer-selective pharmacokinetics and metabolism of ketorolac glycoprotein (Edwards et al). 1999;65:237-44 hildren (Kauffman et al). 1999:65:382-8 Influence of grapefruit juice on cisapride pharmacokinetics (Gross et al). 1999;65:395-401 Guest reviewers Guest reviewers. 1999:65:461 Ecopipam hydrochloride Ecopipam hydrochloride (USAN List No. 416). 1999;65:700 {mitefur Emitefur (USAN List No. 416). 1999:65:701 Haloperidol ‘nalaprilat Effects of the CYP2D6*/0 allele on the steady -State plasma concen Inhibition of angiotensin-converting enzyme in human hand veins trations of haloperidol and reduced haloperidol in Japanese (Chalon et al). 1999:65:58-65 patients with schizophrenia (Mihara et al). 1999;65:291-4 ‘nantiomers. see Stereoisomerism Hand endothelium Inhibition of angiotensin-converting enzyme in human hand veins Angiotensin-converting enzyme inhibition improves venous (Chalon et al). 1999:65:58-65 in chronic smokers (Chalon et al). 1999; Hefilcon A Hefilcon A (USAN List No. 415). 1999;65:591 Hemodialysis Pharmacokinetics of cidofovir in renal insufficiency and in continu ous ambulatory peritoneal dialysis or high-flux hemodialysis enoxacin with the human cytochrome (Brody et al). 1999:65:21-8 hippers et al). 1999;65:262-74 Hemofiltration Pharmacokinetics of meropenem in critically ill patients with acute idomide does not alter estrogen progesterone hormone renal failure undergoing continuous venovenous hemofiltratior yharmacokinetics (Scheffler et al). 1999:65:483-90 (Tegeder et al). 1999:65:50-7 Hilafilcon A Hilafilcon A (USAN List No. 415). 1999;65:591 Histamine agonists FDA. see United States Federal Drug Administration Comparative in vitro and in vivo inhibition of cytochrome P4 Flibanserin CYP1A2, CYP2D6, and CYP3A by H Flibanserin (USAN List No. 416). 1999:65:700 Martinez et al). 1999;65:369-76 Fodipir Hydrocodone Fodipir (USAN List No. 416). 1999:65:699 Analgesic efficacy of a combination of hydrocodone with ibuprofer Forearm in postoperative pain (Wideman et al). 1999;65:66-76 Impaired endothelial-dependent forearm vascular relaxation in black Hydroxylation Americans (Jones et al). 1999:65:408-12 Development of dapsone toxicity in patients with inflammatory der Frovatriptan succinate toses: activity of acetylation and hydroxylation of dapsone as Frovatriptan succinate (USAN List ». 416). 1999:65:698 risk factors (Bluhm et al). 1999;65:598-605 Hypercholesterolemia G Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors (Mas et al). 1999:65:439-47 Ganaxolone Hypertension Ganaxolone (USAN List No. 416). 1999;65:702 The effects of ramipril on sympathetic nervous system function in Gastric acidity determination older patients with hypertension (Lee et al). 1999;65:420-7 CYP2C19 genotype status and effect of omeprazole on intragastric G-protein-coupled receptor kinase expression in hypertension (Gros DH in humans (Furut 1999:65:552-61 et al). 1999;65:545-51 Genotype Impaired endothelial-dependent forearm vascular relaxation in black CYP2C/9 genotype status at ymeprazole on intragastric Americans (Jones et al). 1999:65:408-12 pH in humans (Furuta et al). 1999:65:552-61 Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes (Huang et al). 1999:65:402-7 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of Ibuprofen irinotecan) and bilirubin glucuronidation in human liver tissue with Analgesic efficacy of a combination of hydrocodone with ibuprofen UGTIAI1 promoter polymorphism (Iyer et al). 1999;65:576-82 in postoperative pain (Wideman et al). 1999;65:66-76 CLINICAL PHARMACOLOGY VOLUMI 65, NUMBER 6 Subject inWdile x Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topica fen administration ( egeder et al). 1999:65:357-68 amivudine IGA glomerulonephritis. see Glomerulonephritis, IGA Safety and letticacy of Immunoglobulin A nephropathy. s< Glomerulonephritis, IGA zidovudine an+d |l ami ‘ Immunosuppressive agents anreotide Systemic and intestinal pharmacokinetics of methotrexate in patients UVose-dependent gastrointe with inflammatory bowel disease (Egan et al). 1999;65 19.39 ansoprazole Information dissemination see Communication Theophylline pharmacokineti Injections, intravenous The effect of rifampin on the pharmacokinetics of o1 CYP2C19 poor metabolizers (K yet al 199-65: 606 4 eft ventricular dysfunction. s Ventricular dysfunction, left venous ondanestron (Villikka et al) 1999-65:377-81 etters Inosine monophosphate dehydrogenase Do computational results det PC Induction of inosine monophosphate dehydrogenase activity 1999-65:460 (1 ettte long-term treatment with mycophI enolate mofetil (Sanqu|e r et isinopril 1999-65:640-8 Effects of Interleukin-10 patients Pharmacoimmunodynamic interactions of interleukin-10 and p 1999-65:649-5 nisone in heal 1y volunteers (Chakraborty et al). 1999:65:304 18 Jiver Interleukin-12 Phenotype-genotype corr Down-regulation pharmacokinetic-pharmacodynamic rinotecan) and bilirubin gluct response to during long-term administration promoter polymorpt patients with 1 ‘nal I al). 1999:65:615-29 Lopinavir Irinotecan [ (USAN No +16 Phe notype g type correlation of in vitro SN-38 active metabolite of Losartan irinotecan) and bili ubin glucuronidation in human liver t uc NV id genotypic UGTIAI omotetrel polymorphism (Iyer et al). 1999;65:576-82 the conver s10n Israel 1999-65 Phenotypic-genotypic analysis of CYP2¢ population (Sviri et il). 1999:65:27 5-82 Malaria, cerebral Quin ilaria (Puss 199-65:500 Japanese Malnourishment. s< Nutrition disorders Analysis of the in relation to dextron Meloxicam demethy lati 1 Japan ese population 1999:65:570-5 Methotrexate Syst eCmic al Metoprolol Ketorolac PI arm Enantiomer ective in children (Kauffman Kidney failure, acute Pha irmacokinetics of merope renal failure undergoing continuous yatients W Microcomputers (Tegeder et al). 1999;65:50-7 Dx Kidney failure, chronic 1999-65:4 Pharmacokinetics of cidofovir in renal insufficiency and Microdialysis Ous ambulatory peritoneal dialysis or high-flux he Application o (Brody et al). 1999;65:21 Q suBCULANeCOUS Kidney transplantation fen admini Increase in cerivastatin systemic exposure Midazolam dosing in cyclosporine-treated kidney transplant recipient et al) 1999:65:251-61 ot n id Induction of inosine monophosphate dehydrogenase acti\ Modafinil long-term treatment with mycophenolatet e mot etil (Sanquer Does short erm treatment wit 1999:65:640-8 with obstructive sleep apnea XAPEUTICS l + Sulyect inde NE 1999 Muscle tonus Phenotypic and genotypic investigations of a healthy volunteer defi Pharmacokinetics and pharma namics of SB 209670, cient in the conversion of losartan to its active metabolite E-31 McCrea et al). 1999:65:348-52 ascular tone (Freec Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli Mycophenolate mofetil population (Sviri et al). 1999;65:275-82 nosine monopt pnate Gd ydrogenase Pimozide ofetil (Sanquer et al Effect of clarithromycin on the pharmacokinetics and pharmacody namics of pimozide in healthy poor and extensive metabolizers of cytochrome (Desta et al). 1999;65:10-20 Plasma Clinical pharmacokinetics of encapsulated oral 9-aminocamp tothecin in plasma and saliva (de Jonge et al). 1999;65:491-9 Nitric-oxide synthase Steady-state pharmacokinetics and pharmacodynamics in 1etics of the ase inhibitor L-NY-methy mTeCtU ladone maintenance patients: comparison of holders versus iloride in patients with septic shock (Hussein et nonholders and concentration-effect relationships (Dyer et al) 1999-65:1-9 685-94 Nutrition disorders Pleconaril Ou > disposition ir Pleconaril (USAN List No. 412). 1999:65:79 (Pussal Pneumonia Tobramycin penetration into epi lining fluid of patients with O pneumonia (Carcas et al). 1999:65:245-50 Policosanol omega-N-methylarginine policosanol in pI atients with typI e II hypI ercholesterolemia Pharmacokinetics of the nitric oxide synthase inhibitor 1 additional coronary risk factors (Mas et al). 1999:65:439-47 > hydrochloride in pa Swith s ic shock (Hussein et Polymorphisms 999-65:1-9 Impact of genetic polymorphism > $,-adrenergic receptor on Omeprazole s9ronchodilator pharmacodynamics (Lima et al vitro SN 1 bilirubin glucuronidation i 1999-65:576-8 riSK : OTI Oral contraceptives. Contraceptives, oral Orange juice Phenotypic Prednisone Oxaliplatin Phar Ox Oxybutynin Pregabalin Pr Progesterone Phalidomide jose pharmacokinetic ile Prostaglandin endoperoxide synthase Pain 1 demonstratior 1999-65 1999-65:653-60 Protein kinases G-protein-coupled receptor kir C 999-65:66 il 999-65:545-5 Pediatrics. sec Proto-oncogene proteins c-bcl-2 Pefloxacin nopril administration on blood bc/-2 concentrations i Interac hn Of petioxacin and enoxacin with the human cytoc immunoglobulin A nephropathy (Buemi et al) P450 enzyme CYP1A2 (Kinzig-Schippers et al). 1999;65 999:65:649-52 Pulmonary gas exchange 1 continu *rting enzyme inhibition facilitates alveolar-ca hemodialysis and improves ventilation-perfusion coupling in ventricular dysfunction (Guazzi et a ] P-glycoprotein 1999-65 6’,7’-Dihydroxybergamottin ce fects OI yClospor ycoprotein (Edwards et a Phenotype I -genotype correlation tro SN-38 (active metabolite of Quinine and bilirubin glucuronidation in human liver tissue with Quinine disposition in globally malnourished children with cerebral promoter t ~orphis ret al). 1999:65:576-82 malaria (Pussard et al). 1999:65:500-10